Apellis Pharmaceuticals, Inc. — Director's Dealing 2020

Jan 17, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2020-01-15

Reporting Person: Francois Cedric (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-15	Common Stock	S	26076	$42.159	Disposed	1011355	Direct
2020-01-15	Common Stock	S	4562	$42.547	Disposed	1006793	Direct
2020-01-15	Common Stock	S	5000	$41.47	Disposed	1001793	Direct
2020-01-15	Common Stock	M	30638	$2.14	Acquired	1001793	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-15	Stock Option (Right to Buy)	$2.14	M	30638	Disposed	2020-05-12	Common Stock (30638)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	234411	Indirect

Footnotes

F1: Average Sale Price: Min. $41.46 Max. $42.45

F2: Average Sale Price: Min. $42.46 Max. $42.66

F3: This is a scheduled sale from 10B5-1 trading plan.

F4: This is a scheduled exercise from 10B5-1 trading plan.

F5: The securities are held by The Francois-DuBois Educational Trust (the "Trust"), for which Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.

F6: This option was granted on May 12, 2010 and is fully vested.